High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population

Journal of Gastroenterology

Volumn 44, Issue 4, 2009, Pages 313-321

  Kogiso, Tomomi ^a,b   Moriyoshi, Yuriko ^a   Shimizu, Satoru ^b   Nagahara, Hikaru ^b   Shiratori, Keiko ^b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Akaike information Criterion (AIC); CATegorical data analysis Program (CATDAP 20); High sensitivity C reactive protein (hs CRP); Metabolic syndrome (MS); Multiplelogistic analysis; Nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CIGARETTE SMOKING; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MARKER; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; JAPANESE; LATEX AGGLUTINATION TEST; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; FATTY LIVER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; LATEX FIXATION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEX FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 65049092220     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0002-5     Document Type: Article

References (40)

1. Association of Health and Welfare Statistics. Kokumin eiseinodoukou. Tokyo, Japan: Kokumineisei-kyokai, 2003; pp. 87-96.
2. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. Jpn J Gastroenterol. 2003;38:954-61.
3. The Examination Committee of Criteria for "Obesity Disease" in Japan. Japan Society for Study of Obesity: New criteria for 'obesity disease' in Japan. Circ J. 2002;66:987-92.
4. Shimamoto K. Metabolic syndrome: Epidemiology. Nippon Naika Gakkai Zasshi. 2004;93:642-7.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
6. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III, final report). Circulation 2002;106:3143-421.
7. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-6.
8. Ridker PM, Hennekens CH, Buring JE, Rify N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
9. Block G, Jensen C, Dietrich M, Norkus EP, Hudes M, Packer L. Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. J Am Coll Nutr. 2004;23:141-7.
10. Lowe GD. The relationship between infection, inflammation, and cardiovascular disease: An overview. Ann Periodontol. 2001;6:1-8.
11. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein concentrations. J Am Coll Cardiol. 2005;46:464-9.
12. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature (Lond). 2006;444:881-7.
13. Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK, et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005;69:151-9.
14. Lim S, Lee HK, Kimm KC, Park C, Shin C, Cho NH. C-reactive protein concentration as an independent risk factor of metabolic syndrome in the Korean population CRP as risk factor of metabolic syndrome. Diabetes Res Clin Pract. 2005;70:126-33.
15. Santos AC, Lopes C, Guimaraes JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes Lond. 2005;29:1452-6.
16. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-33.
17. Day CP. Natural history of NAFLD: Remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375-8.
18. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129:113-21.
19. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44-52.
20. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: Another feature of the metabolic syndrome? Clin Nutr. 1999;18:353-8.
21. Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2004;39:864-9.
22. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatits, and the metabolic syndrome. Hepatology. 2003;37:917-23.
23. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: The plot thickens. Diabet Med. 2007;24:1-6.
24. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
25. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-40.
26. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154-60.
27. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005;25:193-7.
28. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19:694-8.
29. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: A case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045-50.
30. Lonardo A, Loria P, Leonardi F, POLI.ST.E.N.A. Study Group, et al. Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid concentrations but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease: A case-control study. Dig Liver Dis. 2002;34:204-11.
31. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164:2169-75.
32. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: Role of insulin resistance. Gut. 2004;53:1020-3.
33. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord. 2004;28:167-72.
34. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. 2nd international symposium on information theory. Budapest: Akademiai Kiado; 1973. pp. 267-81.
35. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics. 2001;57:120-5.
36. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome: prevalence and determinants of a "bright" liver echopattern. Int J Gastenterol Hepatol. 1997;29:351-6.
37. Kogiso T, Moriyoshi Y, Nagahara H. Clinical significance of fatty liver associated with metabolic syndrome. Hepatol Res. 2007;37:711-21.
38. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes. 2005;54:3140-7.
39. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72-82.
40. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-8.